Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy

Decewicz, David J; Neatrour, David M; Burke, Amy; Haberkorn, Mary Jane; Patney, Heather L; Vernalis, Marina N; Ellsworth, Darrell L

doi:10.1186/1476-511X-8-26

Lipids in Health and Disease

Table 2 Changes in lipoprotein subclass measurements and physiological variables by case/control status

From: Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy

	Controls (n = 73)				Participants (n = 73)
Variable	Baseline	Week 12	Week 52	% change	Baseline	Week 12	Week 52	% change	Between group p value^a
Lipoprotein subclass ^b
VLDL and chylomicron particles (nmol/L)
Tot VLDL/chylo	82.0 ± 45.3	80.2 ± 42.6	81.9 ± 47.2	-0.2	87.5 ± 39.6	96.2 ± 43.3	88.5 ± 45.3	+1.2	0.84
Lg VLDL/chylo	4.6 ± 6.3	5.2 ± 6.2	4.5 ± 5.4	-1.2	8.2 ± 6.8	4.7 ± 5.3^c	5.8 ± 7.0^d	-29.4	0.03
Medium VLDL	38.1 ± 28.5	37.4 ± 24.3	37.8 ± 29.5	-0.9	39.7 ± 25.7	49.8 ± 31.8^c	42.0 ± 28.6	+6.0	0.50
Small VLDL	39.3 ± 19.9	37.6 ± 22.1	39.6 ± 19.9	+0.6	39.7 ± 17.2	41.7 ± 18.7	40.7 ± 21.7	+2.6	0.80
LDL particles (nmol/L)
Total LDL	1253 ± 367	1242 ± 422	1249 ± 414	-0.4	1437 ± 477	1291 ± 445^c	1317 ± 452^d	-8.3	0.04
Large LDL	337 ± 211	315 ± 191	317 ± 208	-5.8	251 ± 218	215 ± 152	263 ± 174	+4.5	0.24
Intermed LDL	45.8 ± 38.5	55.6 ± 56.2	43.1 ± 44.6	-5.8	72.6 ± 50.1	50.6 ± 43.4^c	47.3 ± 46.3^c	-34.9	< 0.01
Small LDL	870 ± 434	872 ± 445	888 ± 457	+2.1	1113 ± 478	1025 ± 432	1007 ± 470^d	-9.5	0.04
HDL particles (μmol/L)
Total HDL	34.7 ± 6.7	35.2 ± 6.1	35.2 ± 6.4	+1.7	32.1 ± 5.6	29.0 ± 5.0^c	32.3 ± 5.9	+0.6	0.64
Large HDL	6.4 ± 3.5	6.7 ± 3.3	6.5 ± 3.5	+1.4	4.6 ± 3.4	4.3 ± 2.2	5.2 ± 2.9	+12.7	0.19
Medium HDL	4.9 ± 4.6	5.2 ± 5.1	4.5 ± 4.5	-8.6	5.6 ± 4.7	4.2 ± 4.1^c	5.2 ± 5.3	-7.8	0.70
Small HDL	23.1 ± 7.0	23.0 ± 7.0	24.2 ± 6.7	+4.6	21.7 ± 5.8	20.6 ± 4.7	22.1 ± 6.9	+2.2	0.49
Mean particle sizes (nm)
VLDL size	50.6 ± 9.0	51.8 ± 8.2	50.9 ± 7.5	+0.6	55.6 ± 10.4	48.2 ± 8.6^c	50.2 ± 9.5^c	-9.7	< 0.01
LDL size	20.7 ± 0.9	20.7 ± 0.8	20.7 ± 0.8	-0.2	20.2 ± 0.8	20.2 ± 0.6	20.4 ± 0.7	+0.8	0.03
HDL size	8.8 ± 0.4	8.9 ± 0.4	8.8 ± 0.4	-0.4	8.6 ± 0.3	8.7 ± 0.3	8.7 ± 0.4^d	+1.0	< 0.01
Physiological variables ^e
BMI	28.2 ± 3.7	28.0 ± 3.9	28.3 ± 3.8	+0.4	34.0 ± 7.0	31.4 ± 6.3^c	30.7 ± 6.6^c	-9.9	< 0.01
Systolic BP	133 ± 17	128 ± 15^d	126 ± 13^d	-5.4	136 ± 17	122 ± 14^c	127 ± 16^c	-6.6	0.55
Diastolic BP	78.9 ± 9.2	78.1 ± 8.0	77.3 ± 8.4	-2.0	80.8 ± 9.8	72.6 ± 8.3^c	76.0 ± 9.4^d	-6.0	0.08
HDL	50.5 ± 13.7	51.9 ± 12.7	48.1 ± 13.5^d	-4.9	43.7 ± 13.1	37.5 ± 9.0^c	42.8 ± 10.3	-2.1	0.26
LDL	111 ± 33	110 ± 35	112 ± 36	+1.0	111 ± 39	96 ± 34^c	107 ± 34	-3.9	0.23
Tot cholesterol	191 ± 42	192 ± 45	191 ± 46	+0.2	193 ± 47	167 ± 44^c	183 ± 43^d	-5.5	0.03
Triglycerides	148 ± 100	158 ± 140	152 ± 89	+2.8	189 ± 99	167 ± 73	168 ± 97	-11.3	0.05
Bruce	10.4 ± 2.8	10.6 ± 2.7	10.3 ± 2.8	-1.4	6.6 ± 2.2	8.5 ± 2.3^c	9.0 ± 2.7^c	+37.2	< 0.01
Fram risk	7.2 ± 6.7	6.8 ± 6.5	7.2 ± 7.2	+0.6	11.0 ± 8.6	10.2 ± 8.5^d	10.1 ± 7.8^d	-7.9	< 0.01

Values are presented as mean ± SD; differences between table values and calculated values are due to rounding; % change = week 0–52. a: p values resulting from independent samples t-tests (two-tailed) of Baseline to Week 52 changes in Ornish participants compared to the control group, b: there was no missing data, c: values at Week 12 and Week 52 were significantly different from Baseline at p < 0.001 based on repeated-measures ANOVA with time point as the within-subjects factor and cohort type as the between-subjects factor, d: values at Week 12 and Week 52 were significantly different from Baseline at p < 0.05 based on repeated-measures ANOVA with time point as the within-subjects factor and cohort type as the between-subjects factor, e: there was < 4.2% missing data.

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com